Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.62 |
| ▸ | MTOR | P42345 | 20/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3991341 | 0.99 | PIK3CA (0.61) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| Acetic Acid SCHEMBL27773579 | 0.93 | PIK3CA (0.60) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| SCHEMBL24955563 | 0.90 | PIK3CA (0.51) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| Trifluoroacetic Acid SCHEMBL27794825 | 0.90 | PIK3CA (0.56) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| Tert-Butyl Formate SCHEMBL27773612 | 0.88 | MTOR (0.54) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| SCHEMBL14071906 | 0.86 | PIK3CA (0.62) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| SCHEMBL55549 | 0.83 | PIK3CA (0.45) | PIK3CAMTORPIK3CG | |
| SCHEMBL912539 | 0.82 | MTOR (0.55) | PIK3CAMTORPIK3CGMAPK14CSNK1G1 | |
| SCHEMBL3993542 | 0.82 | PIK3CA (0.43) | PIK3CAMTORPIK3CG | |
| SCHEMBL3986621 | 0.81 | PIK3CA (0.52) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | PIK3CA 2/4885MTOR 1/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.